Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model.
Nakazato
Etsuko
E
Discovery Biology Research, Pfizer Global R&D, Nagoya Laboratories, Taketoyo, Aichi, Japan. Etsuko.Nakazato@japan.pfizer.com
Kato
Aki
A
Watanabe
Shuzo
S
D000700:Analgesics / Q000627:therapeutic use*; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology*; D003250:Constriction; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D007276:Injections, Intraventricular; D008297:Male; D008559:Memantine / Q000627:therapeutic use; D008566:Membranes / Q000187:drug effects / Q000378:metabolism; D010146:Pain / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000188:drug therapy; D010880:Piperidines / Q000627:therapeutic use*; D016548:Prosencephalon / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D013116:Spinal Cord / Q000187:drug effects* / Q000378:metabolism
D000700:Analgesics; D018691:Excitatory Amino Acid Antagonists; C121001:NR2B NMDA receptor; D010880:Piperidines; D016194:Receptors, N-Methyl-D-Aspartate; C095106:traxoprodil mesylate; D008559:Memantine